Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome

Transient headache exacerbation during IV dihydroergotamine (DHE) therapy of migraine may prompt clinicians to prematurely discontinue DHE therapy, potentially depriving patients of the full benefit of DHE infusion. In a recent Neurology® article, Eller et al. evaluated whether or not worsening head...

Full description

Saved in:
Bibliographic Details
Published inNeurology Vol. 87; no. 16; p. e196
Main Authors Woldeamanuel, Yohannes W, O'Hare, Meabh, DeSouza, Danielle D, Cowan, Robert P
Format Journal Article
LanguageEnglish
Published United States 18.10.2016
Subjects
Analgesics, Non-Narcotic
Dihydroergotamine
Headache
Humans
Migraine Disorders
Online AccessGet more information

Cover

More Information
Summary:Transient headache exacerbation during IV dihydroergotamine (DHE) therapy of migraine may prompt clinicians to prematurely discontinue DHE therapy, potentially depriving patients of the full benefit of DHE infusion. In a recent Neurology® article, Eller et al. evaluated whether or not worsening headache during DHE infusion was associated with suboptimal medium-term headache outcomes.
ISSN:1526-632X
DOI:10.1212/WNL.0000000000003230